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Results-based financing (RBF) is subject to fierce debate and the evidence-base 
on its cost effectiveness is scarce. To our knowledge, only one cost-effectiveness 
study of RBF in a lower-middle income country has been published in a peer 
reviewed journal. That study – in Zambia – concludes that RBF is cost-effective, 
which was then uncritically repeated in an editorial accompanying its release. 
Here we would like to warn against readily accepting the conclusion of the cost-
effectiveness study of RBF in Zambia, because its conclusions are not 
straightforward and could be dangerously misleading, especially for those readers 
unfamiliar with health economics. After outlining the results from the Zambia’s 
RBF cost-effectiveness study, we point to important methodological issues 
related to cost-effectiveness analysis, showing how key assumptions produce 
particular results. We then reflect on how cost-effectiveness is different from 
efficiency and affordability – which is important, since cost-effectiveness studies 
often have considerable influence on national health financing strategies and 
policy priorities. Finally, we provide an alternative reading of the evidence on 
RBF in Zambia. Namely, when examined from an efficiency point of view, the 
study actually demonstrates that RBF is less efficient than the simpler alternative 
of providing more resources to health facilities, unconditioned on performance, 
which will be of most interest to a government with tight budget constraints. As a 
result, existing claims that RBF is cost-effective are overstated, requiring further 
and more nuanced examination with more adequate research methods. 




Performance-based financing, pay-for-performance or results-based financing (RBF) is 
implemented in dozens of low- and middle-income countries (LMICs) and remains high 
on the donor agenda. Since 2007, the World Bank has managed the Health Results 
Innovation Trust Fund, a multi-donor fund aimed at disseminating RBF interventions to 
improve maternal and child health (Henrion, Struwig, Wedgwood Young, Guay, & 
Duering, 2018). The World Health Organization is now also supporting the idea that RBF 
is a good entry point for rendering purchasing of health services more strategic (McIsaac, 
Kutzin, Dale, & Soucat, 2018; Soucat, Dale, Mathauer, & Kutzin, 2017). 
However, RBF is subject to significant debate. Concerns have been raised about its 
potential perverse effects and lack of effectiveness, equity, ownership, and sustainability 
(Barnes, Brown, & Harman, 2015; Ireland, Paul, & Dujardin, 2011; Paul, Albert, Bisala, 
et al., & Ridde, 2018; Ridde, Gautier, Turcotte-Tremblay, Sieleunou, & Paul, 2018; 
Seppey, Ridde, Toure, & Coulibaly, 2017; Turcotte-Tremblay, Gali-Gali, De Allegri, & 
Ridde, 2017). In particular, studies have pointed to the high costs of RBF (Borghi, Little, 
Binyaruka, Patouillard, & Kuwawenaruwa, 2015; De Allegri, Makwero, & Torbica, 
2019), and little evidence exists to support its efficiency or value-for-money (Chi et al., 
2018). In 2016, a systematic review was published and identified only seven articles 
examining value-for-money from five LMICs, none of which conducted a full economic 
evaluation and none was exempt from potential conflicts of interests. Moreover, the 
overall strength of the evidence provided by these articles was weak, with no clear 
connection between the costs and effects of RBF (Turcotte-Tremblay, Spagnolo, De 
Allegri, & Ridde, 2016). 
 
Unfortunately, the evidence-base on the cost effectiveness of RBF has not improved 
much since 2016. Based on the three cost effectiveness studies of RBF carried out to date 
in LMICs (in Argentina, Zimbabwe and Zambia), the mid-term evaluation of the Health 
Results Innovation Trust Fund concluded that “evidence on cost effectiveness shows 
some positive results but further study is needed” (Henrion et al., 2018). Moreover, to our 
knowledge, only the cost-effectiveness study in Zambia (Zeng et al., 2018) has been 
published in a peer reviewed academic journal. In that study, Zeng et. al. conclude that 
RBF is cost-effective, which was then uncritically repeated in a World Health 
Organization editorial accompanying the study’s release (McIsaac et al., 2018). 
 
Here we would like to warn against readily accepting the conclusion of the Zeng et. al. 
RBF study, as was so easily done by the World Health Organization. This is because the 
actual conclusions from Zeng et al. are not as straightforward as suggested in the editorial. 
In stronger terms, we see the editorial as a rather lackadaisical treatment of the study, 
which could be dangerously misleading regarding RBF’s overall effects, especially for 
those readers unfamiliar with health economics and who may not understand the impact 
of the original study’s assumptions on cost-effectiveness and/or do not fully understand 
the difference between cost-effectiveness and efficiency. Maintaining this last distinction 
is especially crucial, since cost-effectiveness studies often have considerable influence on 
national health financing strategies and policy priorities. 
Materials and methods 
We proceed below by critically analysing RBF cost-effectiveness in Zambia and review 
it against cost-effectiveness methods. After outlining the results from Zambia’s RBF cost-
effectiveness study, the bulk of our argumentation is structured around three points: (i) 
methodological concerns; (ii) the difference between cost-effectiveness and other 
concepts needed to appropriately appraise RBF holistically; and (iii) our reading of the 
evidence on RBF. 
Results 
The sole academically published cost-effectiveness study on RBF has been that of Zeng 
et. al. (2018), which aimed to evaluate the cost-effectiveness of RBF against the ability 
of input-based financing to increase the use and quality of maternal and child health 
services in rural areas of Zambia. Although labelled a cost-effectiveness study by the 
research team, it was actually more attuned to a cost-utility analysis, since the benefits 
were measured in terms of quality-adjusted life years (QALYs). As a means of 
comparison, the study was based on a cluster-randomized trial having allocated health 
districts to three test groups: 
(1) RBF: increased funding tied to performance on pre-agreed indicators. Health 
facilities under this scheme were required to use at least 40% of the incentive 
payment for operational activities, and the rest for incentives payment to 
personnel. Over the 2.25 years of the programme, 7.91 United States dollars (US$) 
per capita was used in the RBF districts; 
(2) Input-based financing: increased funding not tied to performance. The payment 
received was used only for operational activities. Over the 2.25 year, 2.16 US$ 
per capita was used in the input-based financing districts; 
(3) A pure control group: no additional funding, no indicators. 
Based on a number of research assumptions (see details below), the study found that 
incremental cost-effectiveness ratios (ICER) were 809 US$ per QALY gained through 
RBF, and 413 US$ per QALY gained for the control group receiving input-based 
financing, when compared to the pure control group. From this Zeng et. al. conclude that 
“compared with the control, both results-based financing and input-based financing were 
cost-effective […]”, because the ICERs were “less than 1.5 times the [gross domestic 
product (GDP)] per capita in 2013 in Zambia” (Zeng et al., 2018). 
Discussion 
Cost-effectiveness analysis of RBF and important methodological issues 
Before accepting the conclusion of Zeng et. al. it is important to highlight a number of 
contentious methodological issues regarding cost-effectiveness studies. First, by 
definition, cost-effectiveness analysis ideally aims to compare the full costs and the full 
effects of an intervention, and thus it requires particularly robust modelling assumptions 
for the identification, measurement and valuation of those costs and effects (Chi et al., 
2018). The appropriateness of those models is crucial, since these assumptions have a 
considerable influence on the results. Moreover, this need for sophisticated modelling is 
acknowledged in the World Bank’s assessment toolkit for cost-effectiveness of RBF 
interventions, recommending the further use of sensitivity analyses to test whether 
changes in assumptions change results in a significant manner (Shepard, Zeng, & 
Nguyen, 2015). In the case of the RBF evaluation in Zambia, a number of the assumptions 
used remain highly contested and problematic. The potential effects are that the RBF total 
costs were underestimated along with further assumptions about whether the indicators 
were independent. If this is so, then this has considerable implications for how to 
understand the results. 
 
Second, the ICER of a single intervention cannot tell us much on its own. It is only when 
compared to the ICER of other interventions, or to a given threshold, that it becomes 
meaningful. The World Bank’s toolkit uses the World Health Organization’s “CHOICE” 
categorisation and reckons that an intervention is cost-effective when its ICER ranges 
between one and three times the country’s GDP per capita (Shepard et al., 2015). 
However, there are known problems with using thresholds based on a country’s GDP per 
inhabitant. On one side, if thresholds are set too high they will lead to the inclusion of 
unaffordable interventions (Chi et al., 2018). On the other side, if rough average national 
income measures are used, then this could also result in effective or crucial health 
interventions being withheld from LMICs (The Equitable Access Initiative, 2016). In the 
case of Zambia, RBF could only be judged as cost-effective based on the particular GDP 
threshold chosen by Zeng et. al., but would not have been judged as cost-effective had 
another threshold, which reflected actual budget constraints, been chosen. 
 
Third, cost-effectiveness analysis has been developed to assess simple health 
interventions or technologies, but its application to complex interventions like RBF 
remains a well-recognised challenge. Unlike targeted interventions, RBF is a system-
wide intervention that is subject to system constraints, which will have dynamic impacts 
on various components of the health system. Because of this many scholars have argued 
the need to develop new analytic models to comprehend such system effects (Vassall, 
Bozzani, & Hanson, 2019; Verguet et al., 2019) as well as better modelling to understand 
impacts from other contextual moderators of RBF delivery (Borghi, Singh, Brown, 
Anselmi, & Kristensen, 2018). 
Cost-effectiveness is not to be equated with efficiency and affordability 
As noted above, cost-effectiveness analysis is difficult to apply to complex interventions. 
These difficulties complicate assigning importance to what cost-effectiveness means, 
since it is crucial not to have claims of cost effectiveness confused with conclusions of 
programme efficiency. Unlike cost-effectiveness, efficiency is a broader concept 
encompassing several dimensions: technical efficiency, productive efficiency, and 
allocative efficiency (Reidpath, Olafsdottir, Pokhrel, & Allotey, 2012). Efficiency is a 
concept that describes whether overall programme outcomes (consequences) contribute 
more than the programme costs. Efficiency can be assessed using different tools. The 
ideal one is a cost-benefit analysis that incorporates and weighs all costs and 
consequences – whether related to health or not. In principle, this includes political and 
social consequences as well as more direct effects. Usually, these costs and consequences 
should be quantified in monetary terms. In turn, cost-effectiveness analysis is a narrower 
(but often more pragmatic) tool that focuses on a limited range of measurable 
consequences (mainly mortality in the past, but now broader health effects are taken into 
account through measures such as disability-adjusted life years), which are usually 
limited to the sector impacts only (in this case health impacts). Furthermore, this 
technique can only determine whether something is more efficient than something else 
(on the basis of the narrow range of consequences already mentioned), and not whether 
it is absolutely efficient in contributing more than it costs. Another method to measure 
efficiency is frontier analysis (e.g. Data Envelopment, Stochastic Frontier Analysis), 
which seeks to position various programmes along or below an “efficiency frontier”. 
However, neither cost-effectiveness analysis nor frontier analysis allow for the ranking 
of programmes which are judged equally efficient based on the method’s standard (i.e. 
being judged cost-effective against a given threshold, or being located on the efficiency 
frontier). In other words, while cost-effectiveness analysis and frontier analysis are 
pragmatic tools to measure efficiency, they do it in a rather limited way that do not allow 
assessment of broader costs and consequences to analyse overall value-for-money. New 
techniques enabling researchers to rank policies or programmes, from low to high value, 
are only developing – see for instance the health-adapted super-efficiency data 
envelopment analysis (Shrime, Mukhopadhyay, & Alkire, 2018). However, to our 
knowledge, it has not been applied to RBF. This would be the only way to help assess the 
value of RBF compared to other interventions such as input-based accrued financing. 
 
Moreover, even if an intervention or policy is deemed efficient or cost-effective, it may 
not be affordable due to budget constraints. “Cost effective but unaffordable” 
interventions are “an emerging challenge for health systems” in rich countries (Charlton 
et al., 2017), but it is even more of a challenge in LMICs, where health spending is 
incomparably low (World Health Organization, 2017). Hence, there is a need to 
complement cost-effectiveness analysis with budget impact analysis, so as to make sure 
that prioritised interventions are actually affordable from the payer perspective (Bilinski 
et al., 2017). 
Revisiting RBF in Zambia 
Given the methodological limitations discussed, we believe that the cost-effectiveness 
analysis of RBF in Zambia (Zeng et al., 2018) as well as the editorial accompanying its 
release (McIsaac et al., 2018) overlooked crucial contradictory evidence due to an 
overreliance on unquestioned methodological assumptions and an oversimplified 
analytical framework. When examined from an efficiency point of view, the study 
actually demonstrates that RBF is less efficient than the simpler alternative of providing 
more resources to health facilities, unconditioned on performance. Indeed, in Zambia, a 
moderate, unconstrained input-based payment made available at operational level made 
it possible to gain a QALY for 413 US$, compared to 809 US$ through RBF. At almost 
double the cost per QALY gained, the Zambian RBF mechanism mirrors concerns about 
proportionally high transaction costs associated with RBF in other contexts (Antony, 
Bertone, & Barthes, 2017; Borghi et al., 2015; De Allegri et al., 2019; Kalk, 2011). To 
any policymaker, this is an important consideration when deciding on optimal balances 
within mixed provider payment systems. Particularly so for a government faced with 
limited finances for health. 
As a result, the claim that RBF is cost-effective is in our view overstated and requires 
further and more nuanced examination in light of other measures. This lack of holistic 
nuance is further compounded by the fact that there is actually no consistent evidence on 
RBF effectiveness and efficiency in LMICs (Henrion et al., 2018; Turcotte-Tremblay et 
al., 2016; Wiysonge et al., 2017) – not to mention the growing evidence indicating the 
mixed results and unintended consequences of pay-for-performance in high-income 
countries (Eijkenaar, Emmert, Scheppach, & Schoffski, 2013; Ryan, Krinsky, 
Kontopantelis, & Doran, 2016; Ogundeji, Bland, & Sheldon, 2016; Mendelson et al., 
2017; Forbes, Marchand, Doran, & Peckham, 2017; Gabel, Chambers, Cox, Listl, & 
Maskrey, 2018). 
Conclusion 
Our aim here has been threefold. First, to highlight that there is limited published evidence 
on RBF cost-effectiveness, which underscores the need for a better evidence base. 
Second, to argue that existing research suffers from a number of methodological concerns 
that should temper more enthusiastic generalisations about RBF’s ability to strengthen 
health systems in an affordable way. Most importantly, it is crucial to distinguish claims 
of cost-effectiveness from efficiency, with the latter being a particularly important 
consideration in resource constrained settings. Relatedly, this is particularly the case 
concerning research findings in Zambia, where there is evidence to suggest that input-
based interventions are actually more efficient than RBF. Finally, we wish to conclude 
by noting that it is important to keep these methodological considerations in mind, and to 
be modest in our epistemic claims about RBF, particularly in cases where contested 
evidence is positively echoed within editorials from authoritative institutions like the 
World Health Organization. What is more prudent regarding RBF, in our opinion, is to 
recognise that our research designs and evidence-bases are still evolving, that our research 
methods often remain inadequate or constrained in complex contexts, and that it is never 
good to count your epistemological chickens before they empirically hatch. 
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